ImmunoACT
Recently, ImmunoACT, supported by IIT-B and Laurus Labs, has obtained approval from India's Central Drugs Standard Control Organisation (CDSCO) for its first CAR-T cell therapy, NexCAR19 (Actalycabtagene autoleucel). This treatment targets relapsed/refractory B-cell lymphomas and leukemia.
- NexCAR19 is an indigenous product, representing a significant leap in advanced cell-and-gene therapies. It is a collaborative effort spanning a decade involving IIT-Bombay and Tata Memorial Centre (TMC).
- NexCAR19's approval opens the door for patients in India and resource-constrained countries to access this life-saving therapy at an affordable cost.
- It marks a significant technical achievement, positioning India among the elite nations offering CAR-T therapy.
- ImmunoACT, incubated at IIT ....
Do You Want to Read More?
Subscribe Now
Take Annual Subscription and get the following Advantage
The annual members of the Civil Services Chronicle can read the monthly content of the magazine as well as the Chronicle magazine archives.
Readers can study all the material before the last six months of the Civil Services Chronicle monthly issue in the form of Chronicle magazine archives.
Related Content
- 1 Right to Change Name
- 2 Prevention of Damage to Public Property
- 3 Jan Vishwas (Amendment of Provisions) Act 2023
- 4 Rule 176 vs. Rule 267 of Rajya Sabha
- 5 Digital India Land Records Modernization Programme (DILRMP)
- 6 Right to Silence
- 7 Vibrant Villages Programme
- 8 Bribery Not Protected by Parliamentary Privileges: SC
- 9 SC Directions for Effective Implementation of POSH Act, 2013
- 10 e-Court Phase III
Current Affairs
- 1 Rights of Non-Tribals in Scheduled Areas
- 2 Judicial Recusal
- 3 Data Governance Quality Index (DGQI)
- 4 Article 355
- 5 Governor's Power to Dismiss the Ministers
- 6 Commission of Railway Safety
- 7 Right to Change Name
- 8 Prevention of Damage to Public Property
- 9 Jan Vishwas (Amendment of Provisions) Act 2023
- 10 Rule 176 vs. Rule 267 of Rajya Sabha
